您当前的位置:

Phorbol 12-myristate 13-acetate

(Synonyms: 佛波酯; PMA; TPA; Phorbol myristate acetate)
目录号: PC13649 纯度: ≥98%
Phorbol 12-myristate 13-acetate(PMA; TPA; Phorbol myristate acetate)是一种佛波酯,是蛋白激酶C(PKC)和SphK的激活剂。Phorbol 12-myristate 13-acetate是NF-κB激活剂。Phorbol 12-myristate 13-acetate可诱导THP-1细胞分化。
CAS No. :16561-29-8
商品编号 规格 价格 会员价 是否有货 数量
PC13649-1mg 1mg ¥412.00 请登录
PC13649-5mg 5mg ¥993.00 请登录
PC13649-10mg 10mg ¥1675.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
*注意事项:下单时请联系销售核实产品价格及货期,避免后续产生不便,感谢支持!
中文名称
Phorbol 12-myristate 13-acetate
中文别名
佛波醇12-十四酸酯13-乙酸酯;佛波酯;12-O-十四烷酰佛波-13醋酸酯;12-O-十四烷酰佛波醇-13-乙酸酯;12-O-十四烷酰佛波醋酸酯-13;12-豆蔻酸-13-乙酸佛波醇;12-十四酸酯13-乙酸佛波醇酯;PKC激动剂;佛波醇;佛波醇-12-十四酸酯-13-乙酸酯;佛波酯 PMA;伏波酯;乙酸佛波酯;PMA 佛波酯;豆蔻酰佛波醇乙酯;乙酸佛波酯 PMA;佛波脂酸(5MG/ML)
英文名称
Phorbol 12-myristate 13-acetate
英文别名
Tetradecanoic acid,(1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-9a-(acetyloxy)-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1H-cyclopropa[3,4]benz[1,2-e]azulen-9-ylester;12-O-tetradecanoyl phorbol-13-acetate;4β-Phorbol 12-Myristate 13-Acetate;Invivogen;PHORBOL 12-MYRISTATE 13-ACETATE;PMA;PMA (TPA,Cocarcinogen A1,12-O-Tetradecanoyl-phorbol 13-Acetate,Phorbol 12-myristate 13-acetate);Tetradecanoic acid,(1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-9a-(acetyloxy)-1a,1b,4,4a,5,7a,7b,8,9,9a-de...;12-O-Tetradecanoylphorbol 13-acetate;4β,9α,12β,13α,20-Pentahydroxytiglia-1,6-dien-3-one 12-tetradecanoate 13-acetate;TPA;12-o-tetradecanoyl phorbol acetate;factora1;Cocarcinogen A1;Cocarcinogen C3;pma(tumorpromoter);factora1[crotonoil];factora1(crotonoil);phorbolmyristateacetate;phorbolacetate,myristate;12-O-Tetradecanoylphorbol-13-acetate;,9aalpha))-;Factor A1;Phorbol myristate acetate;Factor A1 (croton oil);Phorbol ester;Tetradecanoylphorbol acetate;PMA (tumor promot
Cas No.
16561-29-8
分子式
C36H56O8
分子量
616.83
包装储存

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

详情描述

Phorbol 12-myristate 13-acetate(PMA; TPA; Phorbol myristate acetate)是一种佛波酯,是蛋白激酶C(PKC)和SphK的激活剂。Phorbol 12-myristate 13-acetate是NF-κB激活剂。Phorbol 12-myristate 13-acetate可诱导THP-1细胞分化。

生物活性

Phorbol 12-myristate 13-acetate (PMA), a phorbol ester, is a dual SphK and protein kinase C (PKC) activator. Phorbol 12-myristate 13-acetate is a NF-κB activator. Phorbol 12-myristate 13-acetate induces differentiation in THP-1 cells.

性状

Solid

IC50 & Target[1][2]

PKC

11.7 nM (EC50)

NF-κB

 

体外研究(In Vitro)

In order to examine the role of PKC in p38MAPK phosphorylation, the cells are stimulated with the PKC activator, PMA (100 nM), which mimics the binding of DAG, the natural activator of PKC, to the C1 region of the PKCs. p38MAPK phosphorylation by PMA is observed in the two cell types similar to that observed by GnRH in αT3-1 cells, that is, a slow sustained activation (3.2-fold and 3.6-fold, respectively at 30 min). The paradoxical findings that PKCs activated by GnRH and PMA play a differential role in p38MAPK phosphorylation may be explained by differential localization of the PKCs. Basal, GnRH- and PMA- stimulation of p38MAPK phosphorylation in αT3-1 cells is mediated by Ca influx via voltage-gated Ca channels and Ca mobilization, while in the differentiated LβT2 gonadotrope cells it is mediated only by Ca mobilization.
THP-1 cells are differentiated into macrophage-like cells (THP-1 macrophages) by incubation in the presence of PMA (200 ng/mL; 1-5 days), which leads to a macrophage-like phenotype characterized by changes in morphology and increased cell surface expression of CD11 and CD14.
In the monocytic cell line THP-1, PMA results in a more differentiated phenotype than VD3, according to adherence, loss of proliferation, phagocytosis of latex beads, and expression of CD11b and CD14.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

PMA is a PKC agonist, which reverses the damage induced by 5-hydroxydecanoic acid (5-HD). Thus, activation of the mitoKATP protected mitochondrial function in SOD and MDA via the PKC pathway.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature or refrigerated transportation.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

结构分类
来源
参考文献
溶解度数据
体外研究: 

DMSO : 100 mg/mL (162.12 mM; Need ultrasonic)

Ethanol : 100 mg/mL (162.12 mM; Need ultrasonic)

配制储备溶液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.6212 mL 8.1060 mL 16.2119 mL
5 mM 0.3242 mL 1.6212 mL 3.2424 mL
10 mM 0.1621 mL 0.8106 mL 1.6212 mL
*

产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时,建议在 6 个月内使用,-20°C 储存时,建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    建议依照次序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (4.05 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.05 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH?O 中,得到澄清透明的生理盐水溶液
  • 2.

    建议依照次序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (4.05 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (4.05 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    建议依照次序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.05 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.05 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

  • 4.

    建议依照次序添加每种溶剂: 10% EtOH    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (4.05 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.05 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH?O 中,得到澄清透明的生理盐水溶液
  • 5.

    建议依照次序添加每种溶剂: 10% EtOH    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (4.05 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (4.05 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 6.

    建议依照次序添加每种溶剂: 10% EtOH    90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.05 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.05 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 900 μL玉米油中,混合均匀。

*
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

相关产品

更多
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2